Ozempic and Wegovy May Help With Chronic Migraine — New Research From the American Academy of Neurology

GLP-1 drugs like semaglutide and tirzepatide were developed for diabetes. Then they transformed obesity treatment. Now researchers are finding benefits that go far beyond either.

A preliminary study released March 1, 2026 — to be presented at the American Academy of Neurology's 78th Annual Meeting in April — found that people with chronic migraine who were taking GLP-1 drugs for another condition (diabetes or weight loss) had meaningfully better migraine outcomes than people taking topiramate, one of the standard preventive migraine drugs.

What the Study Found

Researchers from the University of São Paulo analyzed a health-record database of people with a chronic migraine diagnosis who had also started a GLP-1 drug for another condition. They compared this group against people with chronic migraine who started topiramate during the same period.

The two groups — roughly 11,000 people each — were matched for age, BMI, other health conditions, and prior migraine treatment history.

The GLP-1 group showed:

• Fewer emergency department visits overall
• Fewer hospitalizations
• Less need for acute rescue medications (drugs used to stop a migraine once it starts)
• Less need to try additional preventive medications (a sign their migraines were better controlled)

The GLP-1 drugs studied included liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, and albiglutide.

Important Caveats

This is an observational study using real-world health records. It shows an association — not proof that GLP-1 drugs directly reduce migraine severity or frequency.

People taking GLP-1 drugs for diabetes or weight loss are also changing their diet, potentially losing weight, and experiencing other metabolic improvements — all of which can independently reduce migraine burden. Separating the drug effect from those confounders is hard in this type of study design.

The researchers are clear about this. “The study does not prove that GLP-1 drugs lower the need for emergency care and additional drugs for migraine,” the study notes. “It only shows an association.”

But the signal is there, and it's large enough to be worth attention.

Why This Is Biologically Plausible

GLP-1 receptors are expressed in the central nervous system, not just the gut and pancreas. Researchers have been studying GLP-1 effects on neurological conditions for several years — including Alzheimer's, Parkinson's, and multiple sclerosis — with mixed but promising early results.

The migraine connection has a few possible mechanisms. Chronic migraine has known links to metabolic factors: obesity, insulin resistance, and inflammation all appear to increase migraine frequency. GLP-1 drugs address all three directly. Separately, GLP-1 receptors in brain regions involved in pain processing may play a direct modulatory role — though this remains speculative.

Dr. Vitoria Acar of the University of São Paulo, who led the study, framed it this way: “These therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet.”

What This Means for GLP-1 Patients With Migraines

If you're already on a GLP-1 for weight loss and you also have chronic migraine, this data is worth discussing with your neurologist. The study suggests you may be getting migraine benefits you didn't expect.

If you're considering GLP-1 treatment and you have chronic migraine, this adds one more item to the list of potential benefits beyond weight loss — though migraine management shouldn't be the primary reason to start a GLP-1 drug. That decision still comes down to your metabolic health picture and what your prescriber recommends.

The full study results will be presented at the AAN Annual Meeting in Chicago, April 18–22, 2026. Peer-reviewed publication will likely follow later this year.

The Bigger Pattern

This study adds to a growing list of conditions where GLP-1 drugs show unexpected benefits: heart failure, sleep apnea, liver disease, cognitive function, substance use disorder. What started as a diabetes drug is starting to look like something that works on the fundamental drivers of multiple chronic diseases simultaneously.

Whether that broad effect holds up in larger, randomized controlled trials remains to be seen. But the pattern is consistent enough now that it's hard to dismiss as coincidence.

This article covers a preliminary study presented at AAN 2026 and has not yet been peer-reviewed. Consult your healthcare provider before making any medication decisions. Last updated: March 2026.